Precancerous Lesions in the Kidney

REFERENCES

• Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075–107.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Pisani P. Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827–41.
   Google Scholar
• Van Poppel H, Vandendriessehe H, Boel K, Mertens V, Goethuys H, Haustermans K, et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephreetomy for clinically nonmetastatie renal cell carcinoma. J Urol 1997; 158: 45–9.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865–75.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary meta-stases from renal cell carcinoma: a ease with 5-year followup. J Urol 1992; 148: 1247–8.
   Google Scholar
• Papae RJ. Spontaneous regression of cancer. Cancer Treat Rev 1996; 22: 395–423.
   PubMed Web of Science ®Google Scholar
• Dineen MK, Pastore RD, Emrich LJ, Huben RP. Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 1988; 140: 277–9.
   PubMed Web of Science ®Google Scholar
• Golimbu M, Joshi P. Sperber A, Tessler A, Al-Askari S, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology 1986; 27: 291–301.
   Google Scholar
• Maldazys JD, deKemion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136: 376–9.
   PubMed Web of Science ®Google Scholar
• Middleton RG. Surgery for metastatic renal cell carcinoma. J Urol 1967; 97: 973–7.
   PubMed Web of Science ®Google Scholar
• Wagle DG, Seal DR. Renal cell carcinoma-a review of 256 eases. J Surg Oneol 1970; 2: 23–32.
   PubMedGoogle Scholar
• Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallriehs SL, Trastek VF, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorae Surg 1994; 57: 339–44.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Baert LV. Palliative surgical theraphy. In: Petrovich Z, Baert L, Brady LW, eds. Carcinoma of the kidney and testis, and rare urologie malignancies. Innovations in management. Berlin: Springer-Verlag, 1999: 95–109.
   Google Scholar
• Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161: 381–6.
   PubMed Web of Science ®Google Scholar
• Motzer JR, Vogelzang NJ. Chemotherapy for renal cell carcinoma. In: Raghavan D, Sher HI, Leibel S, Lange P. eds. Principles and practice of genitourinary oncology. New York: Lippincott-Raven, 1997: 885–96.
   Google Scholar
• Bostwick DG, Eble JN, Murphy G. Conference summary: Diagnosis and prognosis of renal cell carcinoma. Cancer 1997; 80: 975–6.
   Google Scholar
• Van Poppel H, Beekers G, Baert L. Prognostic factors in cancer. UICC. Second edition. M. Gospodarowiez et al. (Eds). Wiley, New York 2001 (in press).
   Google Scholar
• Yagoda A, Abi-Raehed B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Surg Oneol 1995; 22: 42–60.
   PubMed Web of Science ®Google Scholar
• Murphy WM, Beckwith JB, Farrow GM Washington, DC: Armed Forces Institute of Pathology, 1994.
   Google Scholar
• True LD, Grignon D. Pathology of renal cancers. In: Raghavan D, Sher HI, Leibel S, Lange P, eds. Principles and practice of genitourinary oncology. New York: Lippincott-Raven, 1997: 799–811.
   Google Scholar
• Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observa-tions on growth. Radiology 1995; 197: 589–97.
   PubMed Web of Science ®Google Scholar
• Ebley JN, Warfeld KA. Precursor lesions and human renal cortical epithelial neoplasia. J Cancer Res Clin Oneol 1990; 116(Suppl): 1228.
   Google Scholar
• Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oneocytomas and carcinomas). The basic cytological and histopathologieal elements and their use for diag-nostics. Pathol Res Praet 1986; 181: 125–43.
   Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131–3.
   PubMed Web of Science ®Google Scholar
• Fleming S, O'Donnell M. Surgical pathology of renal epithelial neoplasms: recent advances and current status. Histopathology 2000; 36: 195–202.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Welter C, Wilkens L, Blin N, DeRiese W. Renal oneocytoma. A phenotypic and genotypic entity of renal parenchymal tumors. Am J Pathol 1989; 134: 967–71.
   Google Scholar
• Lehmann HD, Blessing MH. Renal oneocytoma (path-ology, preoperative diagnosis, therapy). Prog Clin Biol Res 1982; 100: 589–96.
   PubMedGoogle Scholar
• Pearse HD, Houghton DC. Renal oneocytoma. Urology 1979; 13: 74–7.
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VT-IL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85–90.
   PubMed Web of Science ®Google Scholar
• Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994; 3: 2169–73.
   Google Scholar
• Kovacs G. Molecular eytogeneties of renal cell tumors. Adv Cancer Res 1993; 62: 89–124.
   PubMed Web of Science ®Google Scholar
• Kovacs G. The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours. World J Urol 1994; 12: 64–8.
   PubMed Web of Science ®Google Scholar
• Delahunt B, Eble IN. Papillary renal cell carcinoma: a clinicopathologie and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537–44.
   PubMed Web of Science ®Google Scholar
• Bugert P, Gaul C, Weber K, Herbers J, Akhtar M, Ljungberg B, et al. Specific genetic changes of diag-nostic importance in ehromophobe renal cell carcino-mas. Lab Invest 1997; 76: 203–8.
   PubMed Web of Science ®Google Scholar
• Bugert P, Gaul C, Weber K. Specific genetic changes of diagnostic importance in ehromophobe carcinoma. Am J Surg Pathol 1997; 21: 1185–95.
   Google Scholar
• Fleming S, Lewi HJ. Collecting duet carcinoma of the kidney. Histopathology 1986; 10: 1131–41.
   PubMed Web of Science ®Google Scholar
• Rumpelt HJ, Storkel S, Moll R, Seharfe T, Thoenes W. Bellini duet carcinoma: further evidence for this rare variant of renal cell carcinoma. Histopathology 1991; 18: 115–22.
   Google Scholar
• Oberling C, Riviere M, Haguenau F. Ultrastrueture of the clear cells in renal carcinoma and its importance for the demonstrations of their renal origin. Nature 1960; 186: 402.
   Google Scholar
• Delahunt B, Thornton A. Renal cell carcinoma. A historical perspective. J Urol Pathol 1996; 4: 31–49.
   Google Scholar
• Horning ES, Whittiek JVV. The histogenesis of stilboestrol-induced renal tumors in the male golden hamster. Br J Cancer 1954; 8: 451–7.
   PubMed Web of Science ®Google Scholar
• Goldfarb S, Pugh TD. Morphology and anatomic localization of renal mieroneoplasms and proximal tubule dysplasias induced by four different estrogens in the hamster. Cancer Res 1990; 50: 113–9.
   PubMed Web of Science ®Google Scholar
• Lombard LS, Rice IM, Vesselinoviteh SD. Renal tumors in mice: light microscopic observations of epithelial tumors induced by ethylnitrosourea. J Natl Cancer Inst 1974; 53: 1677–85. Scand J Urol Nephrol Suppl 205
   PubMedGoogle Scholar
• Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and patho-logic study of 34 cases. Cancer 1976; 38: 2469–80.
   Google Scholar
• Bernstein J, Evan AP, Gardner Jr KD. Epithelial hyperplasia in human polycystic kidney diseases. Its role in pathogenesis and risk of neoplasia. Am J Pathol 1987; 129: 92–101.
   Google Scholar
• Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic par-ameters in 62 cases. Am J Surg Pathol 1997; 21: 621–35.
   PubMed Web of Science ®Google Scholar
• Kennedy SM, Merino MJ, Linehan WM, Roberts JR, Robertson CN, Neumann RD. Collecting duct carci-noma of the kidney. Hum Pathol 1990; 21: 449–56.
   PubMed Web of Science ®Google Scholar
• Yorukoglu K, Aktas S, Mungan MU, Kirkali Z. Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma. Urology 1999; 53: 684–9.
   PubMed Web of Science ®Google Scholar
• Mourad WA, Nestok BR, Saleh GY, Solez K, Power RF, Jewell LD. Dysplastic tubular epithelium in "normal" kidney associated with renal cell carcinoma. Am J Surg Pathol 1994; 18: 1117–24.
   PubMed Web of Science ®Google Scholar
• Dodd LG, Layfield U. Renal epithelial dysplasia. Am J Surg Pathol 1995; 19: 1335–7.
   PubMed Web of Science ®Google Scholar
• Lai R, el Dabbagh L, Mourad WA. Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion. Mod Pathol 1996; 9: 690–5.
   PubMed Web of Science ®Google Scholar
• Nochomovitz LE, Johansson SL, Merino M, Leslie KO. Recommendations for the reporting of resected neoplasms of the kidney. Association of Directors of Anatomical and Surgical Pathology. Virchows Arch 1996; 428: 71–3.
   Google Scholar
• Eble JN. Recommendations for examining and report-ing tumor-bearing kidney specimens from adults. Semin Diagn Pathol 1998; 15: 77–82.
   PubMed Web of Science ®Google Scholar
• Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 194: 629–42.
   PubMed Web of Science ®Google Scholar
• Solomon D, Schwartz A. Renal pathology in von Hippel-Lindau disease. Hum Pathol 1988; 19: 1072–9.
   PubMed Web of Science ®Google Scholar
• Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carci-noma and no renal disease: clinical implications. J Urol 1995; 154: 2010–4.
   Google Scholar
• Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodia-lysis. Histopathology 1993; 22: 135–9.
   PubMed Web of Science ®Google Scholar
• Fryer AA, Jones PW. Interactions between detoxifying enzyme polymorphisms and susceptibility to cancer. IARC Sci Publ 1999; 148: 303–22.
   PubMedGoogle Scholar
• Hughson MD, Schmidt L, Zbar B, Daugherty S, Meloni AM, Silva FG, et al. Renal cell carcinoma of end-stage renal disease: a histopathologic and molecu-lar genetic study. J Am Soc Nephrol 1996; 7: 2461–8.
   PubMed Web of Science ®Google Scholar
• Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carci-noma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 987–9.
   Google Scholar
• Henn W, Welter C, Wullich B, Zang KD, Blin N, Seitz C. Chromophobe renal cell carcinoma and renal onco-cytoma. A cytogenetic and cytological comparison. J Urol Pathol 1993; 1: 145–55.
   Google Scholar
• Hes O, Michal M, Skalova A. Renal oncocytomas with Hale's colloidal iron positive cytoplasm. J Urol Pathol 1997; 7: 177–87.
   Google Scholar
• Latham B, Dickersin GR, Oliva E. Subtypes of chromophobe cell renal carcinoma: an ultrastructural and histochemical study of 13 cases. Am J Surg Pathol 1999; 23: 530–5.
   Google Scholar
• Störkel S. Chromophobe renal cell carcinoma (differ-ential diagnosis with clear/glanular cell carcinoma and oncocytoma. Rev Esp Pathol 1999; 32: 381–2.
   Google Scholar
• Parkin DM. The global burden of cancer. Semin Cancer Biol 1998; 8: 219–35.
   PubMed Web of Science ®Google Scholar
• Hellsten S, Berge T, Wehlin L. Unrecognized renal cell carcinoma. Clinical and pathological aspects. Scand J Urol Nephrol 1981; 15: 273–8.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Pisani P GLOBOCAN: cancer incidence and mortality worldwide. Lyon, France: IARC Science Publishers, 1998: Cancer Base 3.
   Google Scholar
• McCredie M. Bladder and kidney cancers. Cancer Surv 1994; 19: 343–68.
   PubMedGoogle Scholar
• Chow WH, Devesa SS, Warren It, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628–31.
   Google Scholar
• Nakata S, Ohtake N, Kubota Y, Imai K, Yamanaka H, Ito Y, et al. Incidence of urogenital cancers in Gunma Prefecture, Japan: a 10-year summary. Int J Urol 1998; 5: 364–9.
   PubMedGoogle Scholar
• Pisani P. Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18–29.
   Google Scholar
• Gnarra JR. von Hippel-Lindau gene mutations in human and rodent renal tumors-association with clear cell phenotype. J Nati Cancer Inst 1998; 90: 1685–7.
   PubMedGoogle Scholar
• Maher ER. Inherited renal cell carcinoma. Br J Urol 1996; 78: 542–5.
   PubMedGoogle Scholar
• Zbar B, Glenn G, Lubensky I, Choyke P. Walther MM, Magnusson G, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995; 153: 907–12.
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68–73.
   PubMed Web of Science ®Google Scholar
• Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996; 149: 1201–8.
   PubMed Web of Science ®Google Scholar
• Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syn-drome. Nat Genet 1994; 8: 328–32.
   Google Scholar
• Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C, et al. Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol 1998; 22: 180–7.
   PubMed Web of Science ®Google Scholar
• van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805–8.
   PubMed Web of Science ®Google Scholar
• Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979; 301: 592–5.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Brusa P. De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: devel-opment of multiple bilateral renal-cell carcinomas. Int J Cancer 1989; 43: 422–7.
   Google Scholar
• van den Berg A, Buys CH. Involvement of multiple loci on chromosome 3 in renal cell cancer develop-ment. Genes Chromosomes Cancer 1997; 19: 59–76.
   PubMed Web of Science ®Google Scholar
• van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P. et al. Renal cell cancer: Chromosome 3 translocations as risk factors. J Natl Cancer Inst 1999; 91: 1159–60.
   PubMedGoogle Scholar
• Balzarini P. Dal CM P, Roskams T, Polito P, Van Poppel H, Van Damme B, et al. Histology may depend on the presence of partial monosomy or partial trisomy 3 in renal cell carcinoma. Cancer Genet Cytogenet 1998; 105: 6–10.
   PubMedGoogle Scholar
• van den Berg A, van der Veen AY, Hulsbeek MM, Kovacs G, Gemmill RM, Drabkin HA, et al. Defining the position of the breakpoint of the constitutional t(3;6) occurring in a family with renal cell carcinoma. Genes Chromosomes Cancer 1995; 12: 224–8.
   PubMed Web of Science ®Google Scholar
• Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993; 4: 101–10.
   Google Scholar
• Schlehofer B, Pommer W, Mellemgaard A, Stewart JH, McCredie M, Niwa S, et al. International renal-cell-cancer study. VI. the role of medical and family history. Int J Cancer 1996; 11: 723–6.
   Google Scholar
• Brauch H, Weirich G, Homauer MA, Storkel S, Wohl T, Bruning T. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcino-ma. J Natl Cancer Inst 1999; 91: 854–61.
   PubMed Web of Science ®Google Scholar
• Gabow PA, Bennett WM. Renal manifestations: complication management and long-term outcome of autosomal dominant polycystic kidney disease. Semin Nephrol 1991; 11: 643–52.
   PubMed Web of Science ®Google Scholar
• Zeier M, Geberth S, Ritz E, Jaeger T, Waldherr R. Adult dominant polycystic kidney disease-clinical problems. Nephron 1988; 49: 177–83.
   Google Scholar
• International Agency for Research on Cancer. Tobacco smoking. In: IARC Monograph Evaluation of Carcino-genic Risk of Chemicals to Humans. Lyon, France: IARC, 1986: 35–394.
   Google Scholar
• Doll R. Cancers weakly related to smoking. Br Med Bull 1996; 52: 35–49.
   PubMed Web of Science ®Google Scholar
• McLaughlin JK, Lindblad P. Mellemgaard A, McCre-die M, Mandel JS, Schlehofer B, et al. International renal-cell cancer study. I. Tobacco use. Int J Cancer 1995; 60: 194–8.
   PubMed Web of Science ®Google Scholar
• Muscat JE, Hoffmann D, Wynder EL. The epidemiol-ogy of renal cell carcinoma. A second look. Cancer 1995; 75: 2552–7.
   Google Scholar
• Yuan JM, Castelao JE, Gago-Dominguez M, Yu MC, Ross RK. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol Biomarkers Prey 1998; 7: 429–33.
   Google Scholar
• McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni Jr JF. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst 1984; 72: 275–84.
   Google Scholar
• Hard GC. Experimental models for the sequential analysis of chemically-induced renal carcinogenesis. Toxicol Pathol 1986; 14: 112–22.
   PubMedGoogle Scholar
• Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988; 9: 875–84.
   PubMed Web of Science ®Google Scholar
• Yamasaki E, Ames BN. Concentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proc Natl Acad Sci USA 1977; 74: 3555–9.
   PubMed Web of Science ®Google Scholar
• Shiao YH, Rice JM, Anderson LM, Diwan BA, Hard G. von Hippel-Lindau gene mutations in N-nitroso-dimethylamine-induced rat renal epithelial tumors. J Natl Cancer Inst 1998; 90: 1720–3.
   PubMedGoogle Scholar
• Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and Ti, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56: 3915–25.
   PubMed Web of Science ®Google Scholar
• Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry M, Bouvier R, et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 1999; 59: 2903–8.
   Google Scholar
• Marchand LL, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyp-ing study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prey 1999; 8: 495–500.
   Google Scholar
• Farker K, Lehmann MH, Oelschlagel B, Haerting J, Hoffmann A, Janitzky V, et al. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp Toxicol Pathol 1998; 50: 425–31.
   PubMed Web of Science ®Google Scholar
• Wolk A, Lindblad P. Adami HO. Nutrition and renal cell cancer. Cancer Causes Control 1996; 7: 5–18.
   PubMed Web of Science ®Google Scholar
• Mellemgaard A, Lindblad P. Schlehofer B, Bergstrom R, Mandel JS, McCredie M, et al. International renal-cell cancer study. III. Role of weight, height, physical activity, and use of amphetamines. Int J Cancer 1995; 60: 350–4.
   Google Scholar
• Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer 1998; 77: 1508–13.
   Google Scholar
• Lindblad P. Wolk A, Bergstrom R, Persson I, Adami HO. The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prey 1994; 3: 631–9.
   Google Scholar
• Lindblad P. Mellemgaard A, Schlehofer B, Adami HO, McCredie M, McLaughlin JK, et al. International renal-cell cancer study. V. Reproductive factors, gyne-cologic operations and exogenous hormones. Int J Cancer 1995; 61: 192–8.
   Google Scholar
• Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK (Submitted).
   Google Scholar
• Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994; 57: 123–8.
   Google Scholar
• Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 1987; 47: 1867–9.
   Google Scholar
• Benichou J, Chow WH, McLaughlin JK, Mandel JS, Fraumeni Jr JE. Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol 1998; 148: 424–30.
   Google Scholar
• McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992; 3: 323–31.
   PubMed Web of Science ®Google Scholar
• Talamini R, Baron AE, Barra S, Bidoli E, La Vecchia C, Negri E, et al. A case-control study of risk factors for renal cell cancer in northern Italy. Cancer Causes Control 1990; 1: 125–31.
   PubMed Web of Science ®Google Scholar
• Wynder EL, Mabuchi K, Whitmore Jr WF. Epidemiol-ogy of adenocarcinoma of the kidney. J Natl Cancer Inst 1974; 53: 1619–34.
   PubMed Web of Science ®Google Scholar
• Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986; 77: 351–6.
   Google Scholar
• Cantor KP, Lynch CF, Johnson D. Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control 1993; 4: 505–11.
   Google Scholar
• McLaughlin JK, Gao YT, Gao RN, Zheng W, Ji BT, Blot WJ, et al. Risk factors for renal-cell cancer in Shanghai, China. Int J Cancer 1992; 52: 562–5.
   PubMed Web of Science ®Google Scholar
• Mellemgaard A, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal-cell carcinoma in Denmark. III. Role of weight, physical activity and reproductive factors. Int J Cancer 1994; 56: 66–71.
   PubMed Web of Science ®Google Scholar
• Chow WH, McLaughlin JK, Mandel JS, Blot WJ, Niwa S, Fraumeni Jr JF. Reproductive factors and the risk of renal cell cancer among women. Int J Cancer 1995; 60: 321–4.
   PubMed Web of Science ®Google Scholar
• Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC. Increased risk of renal cell carcinoma subse-quent to hysterectomy. Cancer Epidemiol Biomarkers Prey 1999; 8: 999–1003.
   Google Scholar
• Asal NR, Risser DR, Kadamani S, Geyer JR, Lee ET, Chemg N. Risk factors in renal cell carcinoma: I. Methodology, demographics, tobacco, beverage use, and obesity. Cancer Detect Prey 1988; 11: 359–77.
   PubMedGoogle Scholar
• Adami HO, Persson I, Hoover R, Schairer C, Berg,kvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44: 833–9.
   PubMed Web of Science ®Google Scholar
• Asal NR, Geyer JR, Risser DR, Lee ET, Kadamani S, Chemg N. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detect Prey 1988; 13: 263–79.
   Google Scholar
• Maclure M, Willett W. A case-control study of diet and risk of renal adenocarcinoma. Epidemiology 1990; 1: 430–40.
   PubMedGoogle Scholar
• Chow WH, Lindblad P. Gridley G, Nyren O, McLaughlin JK, Linet MS, et al. Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 1997; 89: 1453–7.
   PubMedGoogle Scholar
• Hiatt RA, Tolan K, Quesenberry Jr CP. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control 1994; 5: 319–25.
   Google Scholar
• McCredie M, Ford JIVI, Stewart JH. Risk factors for cancer of the renal parenchyma. Int J Cancer 1988; 42: 13–6.
   PubMed Web of Science ®Google Scholar
• Rosenberg AG, Dexeus F, Swanson DA, von Eschen-bach AC. Relationship of thyroid disease to renal cell carcinoma. An epidemiologic study. Urology 1990; 35: 492–8.
   Google Scholar
• Tucker MA, Boice Jr JD, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 161–89.
   PubMedGoogle Scholar
• Barista I. An association between renal cell carcinoma and lymphoid malignancies: a case series of eight patients. Cancer 1997; 80: 1004–5.
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994; 70: 950–3.
   PubMed Web of Science ®Google Scholar
• Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell cancer. Am J Epidemiol 1986; 124: 926–41.
   Google Scholar
• Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark: Role of medication and medical history. Int J Epidemiol 1994; 23: 923–30.
   PubMed Web of Science ®Google Scholar
• O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985; 38: 435–41.
   PubMedGoogle Scholar
• Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2: 307–14.
   PubMed Web of Science ®Google Scholar
• Lindblad P, Chow WH, Chan J, Bergstrom A, Wolk A, Gridley G, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999; 42: 107–12.
   PubMed Web of Science ®Google Scholar
• Green A, Jensen OM. Frequency of cancer among insulin-treated diabetic patients in Denmark. Diabeto-logia 1985; 28: 128–30.
   PubMed Web of Science ®Google Scholar
• Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970; 44: 673–86.
   PubMedGoogle Scholar
• Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992; 136: 1110–4.
   PubMed Web of Science ®Google Scholar
• Ishikawa I. Uremic acquired renal cystic disease. Natural history and complications. Nephron 1991; 58: 257–67.
   Google Scholar
• Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol 1994; 4: 1951–6.
   Google Scholar
• Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. Kidney Int 1994; 46: 951–64.
   PubMed Web of Science ®Google Scholar
• Maisonneuve P. Agodoa L, Gellert R, Stewart J, Buccianti G, Lowenfels A, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93–9.
   PubMed Web of Science ®Google Scholar
• Doublet JD, Peraldi MN, Gattegno B, Thibault P. Sraer JD. Renal cell carcinoma of native kidneys: prospec-tive study of 129 renal transplant patients. J Urol 1997; 158: 42–4.
   Google Scholar
• Kliem V. Kolditz M, Behrend M, Ehlerding G, Pichlmayr R, Koch KM, et al. Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 1997; 11: 255–8.
   PubMed Web of Science ®Google Scholar
• Levine LA, Gburek BM. Acquired cystic disease and renal adenocarcinoma following renal transplantation. J Urol 1994; 151: 129–32.
   PubMed Web of Science ®Google Scholar
• Concolino G, Lubrano C, Ombres M, Santonati A, Flammia GP, Di Silverio F. Acquired cystic kidney disease: the hormonal hypothesis. Urology 1993; 41: 170–5.
   Google Scholar
• International Agency for Research on Cancer. Analge-sic mixtures containing phenacetin. In: IARC Mono-graph Evaluation of Carcinogenic Risk of Chemicals to Humans. Updating of IARC Monographs Vols. 1-42. Lyon, France: IARC, 1987: Suppl 7,310–2.
   Google Scholar
• Maclure M, MacMahon B. Phenactin and cancer of urinary tract. N Engl J Med 1985; 313: 1479.
   PubMedGoogle Scholar
• McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer 1993; 53: 245–9.
   PubMed Web of Science ®Google Scholar
• McLaughlin JK, Blot WJ, Mehl ES, Fraumeni Jr JF. Relation of analgesic use to renal cancer: Population-based findings. Natl Cancer Inst Monogr 1985; 69: 217–22.
   Google Scholar
• Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–11.
   PubMed Web of Science ®Google Scholar
• Mellemgaard A, Moller H, Jensen OM, Halberg P. Olsen JH. Risk of kidney cancer in analgesics users. J Clin Epidemiol 1992; 45: 1021–4.
   Google Scholar
• Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999; 81: 542–8.
   Google Scholar
• McCredie M, Pommer W, McLaughlin JK, Stewart JH, Lindblad P. Mandel JS, et al. International renal-cell cancer study. II. Analgesics. Int J Cancer 1995; 60: 345–9.
   PubMed Web of Science ®Google Scholar
• Vane JR, Bolting RM. Mechanism of action of anti-inflammatory drugs. Int J Tissue React 1998; 20: 3–15.
   PubMedGoogle Scholar
• Sabatini S. Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Am J Kidney Dis 1996; 28(Suppl 1): S34–8.
   PubMed Web of Science ®Google Scholar
• Gobe GC, Axelsen RA. The role of apoptosis in the development of renal cortical tubular atrophy asso-ciated with healed experimental renal papillary necro-sis. Pathology 1991; 23: 213–23.
   PubMed Web of Science ®Google Scholar
• Finkle WD, McLaughlin JK, Rasgon SA, Yeoh 1111, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993; 4: 555–8.
   Google Scholar
• Fraser GE, Phillips RL, Beeson WL. Hypertension, antihypertensive medication and risk of renal carcino-ma in California Seventh-Day Adventists. Int J Epidemiol 1990; 19: 832–8.
   Google Scholar
• McLaughlin JK, Blot WJ, Fraumeni Jr JF. Diuretics and renal cell cancer. J Natl Cancer Inst 1988; 80: 378.
   PubMed Web of Science ®Google Scholar
• Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997; 8: 31–6.
   Google Scholar
• Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994; 140: 792–804.
   PubMed Web of Science ®Google Scholar
• Heath Jr CW, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997; 145: 607–13.
   Google Scholar
• McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, McCredie M, Lindblad P. et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995; 9: 216–21.
   Google Scholar
• Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihyperten-sive medication use, and risk of renal cell carcinoma. Am J Epidemiol 1999; 149: 521–30.
   PubMed Web of Science ®Google Scholar
• Buck C, Donner A. Cancer incidence in hypertensives. Cancer 1987; 59: 1386–90.
   PubMed Web of Science ®Google Scholar
• Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. Cancer 1997; 79: 2171–7.
   PubMed Web of Science ®Google Scholar
• Gamble JF, Pearlman ED, Nicolich MJ. A nested case-control study of kidney cancer among refinery/petro-chemical workers. Environ Health Perspect 1996; 104: 642–50.
   Google Scholar
• Raynor Jr WJ, Shekelle RB, Rossof AH, Maliza C, Paul O. High blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol 1981; 113: 371–7.
   Google Scholar
• Wolk A, Gridley G, Niwa S, Lindblad P. McCredie M, Mellemgaard A, et al. International renal cell cancer study. VII. Role of diet. Int J Cancer 1996; 65: 67–73.
   PubMed Web of Science ®Google Scholar
• Yuan JM, Gago-Dominguez M, Castelao JE, Hankin JH, Ross RK, Yu MC. Cruciferous vegetables in relation to renal cell carcinoma. Int J Cancer 1998; 77: 211–6.
   PubMed Web of Science ®Google Scholar
• Lindblad P. Wolk A, Bergstrom R, Adami HO. Diet and risk of renal cell cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prey 1997; 6: 215–23.
   Google Scholar
• Dragsted LO, Strube M, Larsen JC. Cancer-protective factors in fruits and vegetables: biochemical and biological background. Pharmacol Toxicol 1993; 72 (Suppl 1): 116–35.
   Google Scholar
• Hecht SS. Chemoprevention of cancer by isothio-cyanates, modifiers of carcinogen metabolism. J Nutr 1999; 129: 768S–74S.
   Google Scholar
• Mandel JS, McLaughlin JK, Schlehofer B, Mellem-gaard A, Helmert U, Lindblad P. et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995; 61: 601–5.
   PubMed Web of Science ®Google Scholar
• McLaughlin JK, Blot WJ, Devesa SS, Fraumeni Jr JF. Renal cancer. In: Schottenfeld D, Fraumeni JF Jr., eds. Cancer epidemiology and prevention, 2nd edn. New York: Oxford University Press, 1996: 1142–55.
   Google Scholar
• McGregor DB, Heseltine E, Moller H. Dry cleaning, some solvents used in dry cleaning and other industrial chemicals. Scand J Work Environ Health 1995; 21: 310–2.
   Google Scholar
• McLaughlin J, Blot W. A critical review of epidemiol-ogy studies of trichloroethylene and perchloroethylene and risk of renal-cell cancer. Int Arch Occup Environ Health 1997; 70: 222–31.
   PubMed Web of Science ®Google Scholar
• Blair A, Hartge P, Stewart PA, McAdams M, Lubin J. Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: extended follow up. Occup Environ Med 1998; 55: 161–71.
   Google Scholar
• Morgan R, Kelsh M, Zhao K, Heringer S. Mortality of aerospace workers exposed to trichloroethylene. Epi-demiology 1998; 9: 424–31.
   Google Scholar
• Vamvakas S, Bruning T, Thomasson B, Lammert M, Baumuller A, Bolt JIM, et al. Renal cell cancer correlated with occupational exposure to trichloro-ethene. J Cancer Res Clin Oncol 1998; 124: 374–82.
   PubMed Web of Science ®Google Scholar
• Green L, Lash T. Re: "Renal cell cancer correlated with occupational exposure to trichloroethylene". J Cancer Res Clin Oncol 1999; 125: 430–2.
   PubMed Web of Science ®Google Scholar
• Kovacs G. Application of molecular cytogenetic tech-niques to the evaluation of renal parenchymal tumors. J Cancer Res Clin Oncol 1990; 116: 318–23.
   PubMed Web of Science ®Google Scholar
• van den Berg E, Dijkhuizen T, Oosterhuis JW, Geurts van Kessel A, de Jong B, Storkel S. Cytogenetic classification of renal cell cancer. Cancer Genet Cytogenet 1997; 95: 103–7.
   PubMedGoogle Scholar
• Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology 1993; 22: 1–8.
   PubMed Web of Science ®Google Scholar
• Erlandsson R. Molecular genetics of renal cell carcinoma. Cancer Genet Cytogenet 1998; 104: 1–18.
   PubMedGoogle Scholar
• Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995; 22: 3–8.
   PubMed Web of Science ®Google Scholar
• Decker HJ, Weidt EJ, Brieger J. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet 1997; 93: 74–83.
   Google Scholar
• Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317–20.
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700–4.
   PubMed Web of Science ®Google Scholar
• Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcino-mas. Cancer Res 1994; 54: 2852–5.
   PubMed Web of Science ®Google Scholar
• Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 1994; 55: 1092–102.
   PubMed Web of Science ®Google Scholar
• Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996; 75: 231–8.
   PubMed Web of Science ®Google Scholar
• Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, et al. Somatic mutations of the von Hippel- Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994; 54: 4845–7.
   PubMed Web of Science ®Google Scholar
• Oberstrass J, Reifenberger G, Reifenberger J, Wechsler W, Collins VP. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblasto-mas of the central nervous system. J Pathol 1996; 179: 151–6.
   Google Scholar
• Kenck C, Wilhelm M, Bugert P. Staehler G, Kovacs G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996; 179: 157–61.
   Google Scholar
• Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343–50.
   PubMed Web of Science ®Google Scholar
• Consortium ECTS. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Con-sortium. Cell 1993; 75: 1305–15.
   Google Scholar
• Carbonara C, Longa L, Grosso E, Mazzucco G, Borrone C, Garre ML, et al. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromoso-mal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer 1996; 15: 18–25.
   PubMed Web of Science ®Google Scholar
• Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994; 6: 193–6.
   Google Scholar
• Henske EP, Neumann HP, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of hetero-zygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chro-mosomes Cancer 1995; 13: 295–8.
   PubMed Web of Science ®Google Scholar
• Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 1996; 33: 962–4.
   Google Scholar
• Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. Urology 1991; 37: 340–3.
   PubMed Web of Science ®Google Scholar
• Hadaczek P. Siprashvili Z, Markiewski M, Domagala W, Druck T, McCue PA, et al. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 1998; 58: 2946–51.
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356–62.
   Google Scholar
• Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997; 57: 5221–5.
   PubMed Web of Science ®Google Scholar
• Velickovic M, Delahunt B, Grebe SK. Loss of hetero-zygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 1999; 59: 1323–6.
   Google Scholar
• Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel Lindau tumor suppressor gene for functional EGF receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clinical Cancer Res 2000: in press.
   Google Scholar
• Kalble T, Kovacs G. Molecular genetics in the diag-nosis and prognosis of renal cancer. Klin Lab 1994; 40: 1209–34.
   Google Scholar
• Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 1997; 183: 151–5.
   Google Scholar
• Dal CMP, van Poppel H, van Damme B, Baert L, Van den Berghe H. Cytogenetic investigation of synchro-nous bilateral renal tumors. Cancer Genet Cytogenet 1996; 89: 57–60.
   PubMedGoogle Scholar
• Lubensky IA, Gnarra JR, Bertheau P. Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996; 149: 2089–94.
   Google Scholar
• Nakagawa M, Emoto A, Hanada T, Nasu N, Nomura Y. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma. Br J Urol 1997; 79: 681–7.
   Google Scholar
• Nicol D, Hii SI, Walsh M, Teh B, Thompson L, Kennett C, et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 1997; 157: 1482–6.
   PubMed Web of Science ®Google Scholar
• Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996; 56: 2299–301.
   Google Scholar
• Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999; 35: 133–7.
   PubMed Web of Science ®Google Scholar
• Bugert P. Kenck C, Wilhelm M, Kovacs G. Refining a proximal breakpoint cluster at chromosome 3p11.2 in non-papillary renal cell carcinomas. Int J Cancer 1996; 68: 723–6.
   Google Scholar
• Beroud C, Foumet JC, Jeanpierre C, Droz D, Bouvier R, Froger D, et al. Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas. Genes Chromosomes Cancer 1996; 17: 215–24.
   PubMed Web of Science ®Google Scholar
• Hofmockel G, Wittmann A, Dammrich J, Bassukas ID. Expression of p53 and bc1-2 in primary locally con-fined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 1996; 16: 3807–11.
   PubMed Web of Science ®Google Scholar
• Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994; 7: 766–70.
   Google Scholar
• Jennings SB, Gnarra JR, Walther MM, Zbar B, Linehan WM. Renal cell carcinoma. Molecular genet-ics and clinical implications. Surg Oncol Clin N Am 1995; 4: 219–29.
   Google Scholar
• Nishiyama Y, Suwa H, Okamoto K, Fukumoto M, Hiai H, Toyokuni S. Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor sup-pressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilo-triacetate. Jpn J Cancer Res 1995; 86: 1150–8.
   PubMedGoogle Scholar
• Reiter RE, Anglard P. Liu S, Gnarra JR, Linehan WM. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 1993; 53: 3092–7.
   Google Scholar
• Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K. Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol 1993; 150: 1298–301.
   PubMed Web of Science ®Google Scholar
• Uchida T, Wada C, Wang C, Egawa S, Ohtani H, Koshiba K. Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. Cancer Res 1994; 54: 3682–5.
   PubMed Web of Science ®Google Scholar
• Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995; 55: 224–7.
   PubMed Web of Science ®Google Scholar
• Dal CMP, Gaeta J, Huben R, Li FP, Prout Jr GR, Sandberg AA. Renal cortical tumors. Cytogenetic characterization. Am J Clin Pathol 1989; 92: 408–14.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytoge-netics of papillary renal cell tumors. Genes Chromo-somes Cancer 1991; 3: 249–55.
   PubMed Web of Science ®Google Scholar
• Brown JA, Anderl KL, Bore11 TJ, Qian J, Bostwick DG, Jenkins RB. Simultaneous chromosome 7 and 17 gain and sex chromosome loss provide evidence that renal metanephric adenoma is related to papillary renal cell carcinoma. J Urol 1997; 158: 370–4.
   Google Scholar
• Stumm M, Koch A, Wieacker PF, Phillip C, Steinbach F, Allhoff EP, et al. Partial mono somy 2p as the single chromosomal anomaly in a case of renal metanephric adenoma. Cancer Genet Cytogenet 1999; 115: 82–5.
   PubMedGoogle Scholar
• Kattar MM, Grignon DJ, Wallis T, Haas GP, Sakr WA, Pontes JE, et al. Clinicopathologic and interphase cytogenetic analysis of papillary (chromophilic) renal cell carcinoma. Mod Pathol 1997; 10: 1143–50.
   PubMed Web of Science ®Google Scholar
• Dal CMP, Stas M, Sciot R, De Weyer I, Van Damme B, Van den Berghe H. Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet Cytogenet 1998; 101: 58–61.
   Google Scholar
• Weterman MA, Wilbrink M, Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 1996; 93: 15294–8.
   Google Scholar
• Shuin T, Kondo K, Sakai N, Kaneko S, Yao M, Nagashima Y, et al. A case of chromophobe renal cell carcinoma associated with low chromosome number and microsatellite instability. Cancer Genet Cytogenet 1996; 86: 69–71.
   PubMedGoogle Scholar
• Speicher MR, Schoen B, du Manoir S, Schrock E, Ried T, Cremer T, et al. Specific loss of chromosomes 1,2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridi-zation. Am J Pathol 1994; 145: 356–64.
   PubMed Web of Science ®Google Scholar
• Neuhaus C, Dijkhuizen T, van den Berg E, Storkel S, StocIde M, Mensch B, et al. Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review. Cancer Genet Cytogenet 1997; 94: 95–8.
   Google Scholar
• Dal CMP, Van den Berghe H, Van Poppel H, Roskams T. Involvement of 12q12-13 is a nonrandom chromo-some change in renal oncocytoma. Genes Chromo-somes Cancer 1999; 24: 94.
   PubMed Web of Science ®Google Scholar
• Cavazzana AO. Bellini duct carcinoma. A clinical and in vitro study. Eur Urol 1996; 30: 340–4.
   PubMed Web of Science ®Google Scholar
• Fuzesi L, Cober M, Mittermayer C. Collecting duct carcinoma: cytogenetic characterization. Histopathol-ogy 1992; 21: 155–60.
   Google Scholar
• Gregori-Romero MA, Morell-Quadreny L, Llombart-Bosch A. Cytogenetic analysis of three primary Bellini duct carcinomas. Genes Chromosomes Cancer 1996; 15: 170–2.
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF, et al. Distal nephron renal tumors: micro-satellite allelotype. Cancer Res 1996; 56: 1892–5.
   PubMed Web of Science ®Google Scholar
• Schoenberg M, Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, et al. Frequent loss of chromo-some arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer 1995; 12: 76–80.
   PubMed Web of Science ®Google Scholar
• Johansson B, Heim S, Mandahl N, Mertens F, Mitel-man F. Trisomy 7 in nonneoplastic cells. Genes Chromosomes Cancer 1993; 6: 199–205.
   PubMed Web of Science ®Google Scholar
• Elfving P. Aman P. Mandahl N, Lundgren R, Mitelman F. Trisomy 7 in nonneoplastic epithelial kidney cells. Cytogenet Cell Genet 1995; 69: 90–6.
   PubMedGoogle Scholar
• Dal CMP, Aly MS, Delabie J, Ceuppens IL, Van Gool S, Van Damme B, et al. Trisomy 7 and trisomy 10 characterize subpopulations of tumor-infiltrating lym-phocytes in kidney tumors and in the surrounding Scand J Urol Nephrol Suppl 205 kidney tissue. Proe Natl Aead Sei USA 1992; 89: 9744–8.
   Google Scholar
• Eker R, Mossige J. A dominant gene for renal adenomas in the rat. Nature 1961; 189: 858–9.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tse2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 1995; 9: 70–4.
   Google Scholar
• Walker C, Goldsworthy TL, Wolf DC, Everitt J. Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science 1992; 255: 1693–5.
   PubMed Web of Science ®Google Scholar
• Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proe Natl Aead Sei USA 1994; 91: 11413–6.
   PubMed Web of Science ®Google Scholar
• Everitt JI, Walker CL, Goldsworthy TW, Wolf DC. Altered expression of transforming growth factor-alpha: an early event in renal cell carcinoma develop-ment. Mol Careinog 1997; 19: 213–9.
   PubMed Web of Science ®Google Scholar
• Bazeed MA, Seharfe T, Becht E, Jurincie C, Alken P. Thuroff JW. Conservative surgery of renal cell carcinoma. Eur Urol 1986; 12: 238–43.
   Google Scholar
• Herr HW. Partial nephreetomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol 1999; 161: 33–4.
   PubMed Web of Science ®Google Scholar
• Lerner SE, Tsai H, Flanigan RC, Trump DL, Fleisehmann J. Renal cell carcinoma: considerations for nephron-sparing surgery. Urology 1995; 45: 574–7.
   Google Scholar
• Morgan WR, Zineke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990; 144: 852–7.
   PubMed Web of Science ®Google Scholar
• Novick AC. Partial nephreetomy for renal cell carcinoma. Urology 1995; 46: 149–52.
   PubMed Web of Science ®Google Scholar
• Petritseh PH, Rauehenwald M, Zeehner O, Ludvik W, Pummer K, Urlesberger H, et al. Results after organ-preserving surgery for renal cell carcinoma. An Austrian multicenter study. Eur Urol 1990; 18: 84–7.
   Google Scholar
• Provet J, Tessler A, Brown J, Golimbu M, Bosniak M, Morales P. Partial nephreetomy for renal cell carcino-ma: indications, results and implications. J Urol 1991; 145: 472–6.
   PubMed Web of Science ®Google Scholar
• Selli C, Lapini A, Carini M. Conservative surgery of kidney tumors. Prog Clin Biol Res 1991; 370: 9–17.
   PubMedGoogle Scholar
• Steinbach F, Stoekle M, Muller SC, Thuroff JVV, Melchior SW, Stein R, et al. Conservative surgery of renal cell tumors in 140 patients: 21 years of experi-ence. J Urol 1992; 148: 24–9.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Claes H, Willemen P. Oyen R, Baert L. Is there a place for conservative surgery in the treat-ment of renal carcinoma? Br J Urol 1991; 67: 129–33.
   Google Scholar
• van Poppel HP, Bamelis F, Baert LV. Non-metastatic renal cell eareinoam. Curr Opin Urol 1996; 6: 241–4.
   Google Scholar
• Wunderlich H, Reiehelt O, Schumann S, Schlichter A, Kosmehl H, Werner W, et al. Nephron sparing surgery for renal cell carcinoma 4 em. or less in diameter: indicated or under treated? J Urol 1998; 159: 1465–9.
   Google Scholar
• Van Poppel H, Baert LV. Nephron-sparing surgery. In: Petrovich Z, Baert L, Brady LW, eds. Carcinoma of the kidney and testis, and rare urologie malignancies. Innovations in management. Berlin: Springer-Verlag, 1999: 79–93.
   Google Scholar
• Curry NS, Sehabel SI, Betsill Jr WL. Small renal neoplasms: diagnostic imaging, pathologic features, and clinical course. Radiology 1986; 158: 113–7.
   Google Scholar
• Foster WL, Halvorsen RA, Dunniek NR. The clandes-tine renal cell carcinoma: atypical appearances and presentations. Radiographies 1985; 5: 175–92.
   Google Scholar
• Kavoussi LR, Torrence RJ, Catalona WJ. Renal oneocytoma with synchronous contralateral renal cell carcinoma. J Urol 1985; 134: 1193–6.
   Google Scholar
• London NJ, Messios N, Kinder RB, Smart JG, Osborn DE, Watkin EM, et al. A prospective study of the value of conventional et, dynamic et, ultrasonography and arteriography for staging renal carcinoma. Br J Urol 1989; 64: 209–17.
   PubMedGoogle Scholar
• Van Poppel H, Bamelis B, Baert L. Elective nephron-sparing surgery for renal cell carcinoma. European Urologieal Update Series (EUUS) 1997; 6: 8–12.
   Google Scholar
• Moll V, Becht E, Ziegler M. Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients. J Urol 1993; 150: 319–23.
   Google Scholar
• Carini M, Selli C, Barbanti G, Lapini A, Turini D, Costantini A. Conservative surgical treatment of renal cell carcinoma: clinical experience and reappraisal of indications. J Urol 1988; 140: 725–31.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Bamelis B, Oyen R, Baert L. Partial nephreetomy for renal cell carcinoma can achieve long-term tumor control. J Urol 1998; 160: 674–8.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Baert LV. Organ-sparing surgery: magic bullet or tragic insanity? In: Kurth KH, Mickisch GH, Schröder FH, eds. Renal, bladder and prostatie cancer, an update. New York: Parthenon-Publishing Group, 1999: 23–9.
   Google Scholar
• Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997; 157: 2067–70.
   Google Scholar
• Holthöfer H. Immunohistology of renal carcinomas. Eur Urol 1990; 18\(Supp12): 15–6.
   Google Scholar
• Bennington M. Proceedings: Cancer of the kidney-etiology, epidemiology, and pathology. Cancer 1973; 32: 1017–29.
   PubMed Web of Science ®Google Scholar
• Bell ET Renal diseases, 2nd edn. Philadelphia, PA: Lea and Febiger, 1950.
   Google Scholar
• Hajdu SI, Thomas AG. Renal cell carcinoma at autopsy. J Urol 1967; 97: 978–82.
   PubMed Web of Science ®Google Scholar
• Mukamel E, Koniehezky M, Engelstein D, Servadio C. Incidental small renal tumors accompanying clinically overt renal cell carcinoma. J Urol 1988; 140: 22–4.
   PubMed Web of Science ®Google Scholar
• Esehwege P. Saussine C, Steiehen G, Delepaul B, Drelon L, Jaeqmin D. Radical nephreetomy for renal cell carcinoma 30 mm. or less: long-term follow results. J Urol 1996; 155: 1196–9.
   Google Scholar
• Cheng WS, Farrow GM, Zineke H. The incidence of multicentricity in renal cell carcinoma. J Urol 1991; 146: 1221–3.
   Google Scholar
• Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR. Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995; 45: 34–41.
   Google Scholar
• Holland JM. Proceedings: Cancer of the kidney-natural history and staging. Cancer 1973; 32: 1030–42.
   PubMed Web of Science ®Google Scholar
• Xipell JM. The incidence of benign renal nodules (a clinicopathologie study). J Urol 1971; 106: 503–6.
   PubMed Web of Science ®Google Scholar
• Olsen S Tumors of the kidney and urinary tract. Copenhagen: Munsgaard, 1984.
   Google Scholar
• Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35: 1332–8.
   PubMedGoogle Scholar
• Hanash KA, Aquilina JVV, Barrett DM, Blute ML, Cockett AT, Corica FA, et al. Clinical research priori-ties in renal cell carcinoma: renal cell carcinoma chemo-prevention strategies including target populations, proposed agents, and clinical trial designs-Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the Ame. Cancer 1997; 80: 999–1001.
   Google Scholar
• Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol 1999; 161: 1748–60.
   PubMed Web of Science ®Google Scholar
• Malvy DJ, Burtschy B, Arnaud J, Sommelet D, Leverger G, Dostalova L, et al. Serum beta-carotene and antioxidant micronutrients in children with cancer. The 'Cancer in Children and Antioxidant Micronu-trients' French Study Group. Int J Epidemiol 1993; 22: 761–71.
   Google Scholar
• Ryuto M, Jimi S, Ono M, Naito S, Nakayama Y, Yamada Y, et al. All-trans-retinoic acid-dependent inhibition of E-cadherin-based cell adhesion with concomitant dephosphorylation of beta-catenin in meta-static human renal carcinoma cells. Jpn J Cancer Res 1997; 88: 982–91.
   PubMedGoogle Scholar
• Liehr JG. Vitamin C reduces the incidence and severity of renal tumors induced by estradiol or diethylstilbes-trol. Am J Clin Nutr 1991; 54: 1256S–60S.
   Google Scholar
• Nikiforova NV, Chumakov AM, Kirpatovskii VI, Komarova VA. Fat-soluble vitamins E and A in the tumor tissue and in the blood of patients with renal-cell cancer. Urol Nefrol (Mosk) 1996; 6: 23–7.
   Google Scholar
• Okamoto T, Fujioka T, Horiuchi S. A study of the metabolism of vitamin D in patients with renal cell carcinoma-with special reference to serum concen-tration of 1 alpha, 25-(OH)2D and its clinical signi-ficance. Nippon Hinyokika Gakkai Zasshi 1991; 82: 890–9.
   Google Scholar
• Fujioka T, Hasegawa M, Ishikura K, Matsushita Y, Sato M, Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 1998; 160: 247–51.
   PubMed Web of Science ®Google Scholar
• Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C. Prognostic significance of incidental renal cell carcinoma. Eur Urol 1995; 27: 319–23.
   Google Scholar
• Filipas D, Spix C, Schultz-Lampel D, Black P, Kater B, Roth S, et al. Pilotstudie zur sonographischen Fruher-kennung des Nierenzellkarzinoms. Radiologe 1999; 39: 350–3.
   Google Scholar
• Mihara S, Nagano K, Kuroda K, Yoshioka R, Sawatari M, Koba H, et al. Efficacy of ultrasonic mass survey for abdominal cancer. J Med Syst 1998; 22: 55–62.
   PubMedGoogle Scholar
• Sekido N, Shimazui T, Noguchi R, Akaza H, Koiso K. Transabdominal ultrasonography for detection of urologic diseases in the general health check. Nippon Hinyokika Gakkai Zasshi 1994; 85: 1089–96.
   PubMedGoogle Scholar
• Horii Y, Tsumatani K, Natsume O, Uemura H, Sasaki K, Komada S, et al. Usefulness of computed tomo-graphy and ultrasonography for the early detection of renal cell carcinoma. Hinyokika Kiyo 1987; 33: 998–1004.
   PubMedGoogle Scholar
• Rinsho K, Ishikawa S, Uchida K, Koiso K. The value of ultrasonography in early detection of renal cell carcinoma. Jpn J Clin Oncol 1984; 14: 329–34.
   PubMed Web of Science ®Google Scholar
• Cochrane AL, Holland WW. Validation of screening procedures. Br Med Bull 1971; 27: 3–8.
   PubMed Web of Science ®Google Scholar
• Hes FJ, Feldberg MA. Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancrea-tic masses). Eur Radiol 1999; 9: 598–610.
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Wong JB, Levey AS, Meyer KB. Screening for acquired cystic kidney disease: a decision analytic perspective. Kidney Int 1995; 48: 207–19.
   PubMed Web of Science ®Google Scholar
• Curley SA, Lott ST, Luca JW, Frazier ML, Killary AM. Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. Ann Surg 1998; 227: 229–35.
   Google Scholar
• Bretan Jr PN. Acquired renal cystic disease: is there a need for screening for renal cell carcinoma in patients with renal failure? Semin Urol 1994; 12: 89–92.
   PubMedGoogle Scholar
• Shapiro JA, Williams MA, Weiss NS. Body mass index and risk of renal cell carcinoma. Epidemiology 1999; 10: 188–91.
   Google Scholar
• Licht MR, Novick AC, Goormastic M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 1994; 152: 39–42.
   Google Scholar
• Brisset JM, Lugagne PM, Veillon B, Vallancien G, Charton M, Andre-Bougaran J. Parenchymal-sparing surgery for small renal cell cancer: are there any reasonable arguments? Prog Clin Biol Res 1989; 303: 153–9.
   Google Scholar
• Steinbach F, StocIde M, Thuroff JVV, Storkel S, Melchior SW, Kiewel R, et al. Long-term experience with conservative surgery of renal tumors. Surgical technique, complications, results, DNA-cytometry. Scand J Urol Nephrol Suppl 1991; 138: 207–13.
   PubMedGoogle Scholar
• Taari K, Salo JO, Rannikko S, Karkkainen P. Nordling S, Lehtonen T. Parenchyma-conserving surgery for renal cell carcinoma. Ann Chir Gynaecol Suppl 1993; 206: 54–8.
   PubMedGoogle Scholar
• D'Armiento M, Damiano R, Feleppa B, Perdona S, Oriani G, De Sio M. Elective conservative surgery for renal carcinoma versus radical nephrectomy: a pro-spective study. Br J Urol 1997; 79: 15–9.
   PubMedGoogle Scholar